Literature DB >> 1549227

Botulinum toxin therapy for limb dystonias.

D M Yoshimura1, M J Aminoff, R K Olney.   

Abstract

We investigated the effectiveness of botulinum toxin in 17 patients with limb dystonias (10 with occupational cramps, three with idiopathic dystonia unrelated to activity, and two each with post-stroke and parkinsonian dystonia) in a placebo-controlled, blinded study. We identified affected muscles clinically and by recording the EMG from implanted wire electrodes at rest and during performance of tasks that precipitated abnormal postures. There were three injections given with graded doses of toxin (average doses, 5 to 10, 10 to 20, and 20 to 40 units per muscle) and one with placebo, in random order. Subjective improvement occurred after 53% of injections of botulinum toxin, and this was substantial in 24%. Only one patient (7%) improved after placebo injection. Subjective improvement occurred in 82% of patients with at least one dose of toxin, lasting for 1 to 4 months. Response rates were similar between clinical groups. Objective evaluation failed to demonstrate significant improvement following treatment with toxin compared with placebo. The major side effect was transient focal weakness after 53% of injections of toxin.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1549227     DOI: 10.1212/wnl.42.3.627

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  25 in total

Review 1.  Botulinum toxin for the treatment of movement disorders.

Authors:  Mary Ann Thenganatt; Stanley Fahn
Journal:  Curr Neurol Neurosci Rep       Date:  2012-08       Impact factor: 5.081

2.  Botulinum toxin for writer's cramp: a randomised, placebo-controlled trial and 1-year follow-up.

Authors:  J J M Kruisdijk; J H T M Koelman; B W Ongerboer de Visser; R J de Haan; J D Speelman
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-12-21       Impact factor: 10.154

Review 3.  Treatment of dystonia.

Authors:  Mary Ann Thenganatt; Joseph Jankovic
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

4.  Botulinum toxin in writer's cramp: objective response evaluation in 31 patients.

Authors:  J Wissel; C Kabus; R Wenzel; S Klepsch; U Schwarz; A Nebe; L Schelosky; U Scholz; W Poewe
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-08       Impact factor: 10.154

Review 5.  An update on the use of botulinum toxin therapy in Parkinson's disease.

Authors:  Reversa Mills; Laxman Bahroo; Fernando Pagan
Journal:  Curr Neurol Neurosci Rep       Date:  2015-01       Impact factor: 5.081

6.  Isolated idiopathic adult-onset foot dystonia and treatment with botulinum toxin.

Authors:  J Duarte; A P Sempere; F Coria; L E Clavería; F A Frech; A L Mataix; E Martinez
Journal:  J Neurol       Date:  1995-01       Impact factor: 4.849

7.  Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

Authors:  D M Simpson; A Blitzer; A Brashear; C Comella; R Dubinsky; M Hallett; J Jankovic; B Karp; C L Ludlow; J M Miyasaki; M Naumann; Y So
Journal:  Neurology       Date:  2008-05-06       Impact factor: 9.910

8.  Botulinum toxin F in the treatment of torticollis clinically resistant to botulinum toxin A.

Authors:  G L Sheean; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-12       Impact factor: 10.154

Review 9.  Treatment of Dystonia: Medications, Neurotoxins, Neuromodulation, and Rehabilitation.

Authors:  Ian O Bledsoe; Aaron C Viser; Marta San Luciano
Journal:  Neurotherapeutics       Date:  2020-10-23       Impact factor: 7.620

Review 10.  Treatment of focal dystonias with botulinum neurotoxin.

Authors:  Mark Hallett; Reiner Benecke; Andrew Blitzer; Cynthia L Comella
Journal:  Toxicon       Date:  2008-12-13       Impact factor: 3.033

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.